Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

On the heels of the premiere of its first-ever Spanish-language Cologuard campaign, Exact Sciences is doubling down on its ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

At the beginning of October, the FDA approved the Cologuard Plus test, a next-generation, multitarget stool DNA test. While fecal testing is a good option for some patients, colonoscopy remains the ...

Enter Cologuard, the at-home colon cancer screening test for people aged 45 and older. Perhaps best known by audiences for its cheeky approach to advertising, the Exact Sciences brand recently ...

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...

Exact's main sources of revenues are its Cologuard test, a "patient-friendly, non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Hello. At this time, I would like to welcome everyone to the Exact Sciences. Third quarter, 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to Erik ...